Search results
Results from the WOW.Com Content Network
Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. [1] Dopamine receptors are therefore common drug targets. Dopamine receptors activate different effectors through not only G-protein coupling, but also signaling through different protein (dopamine receptor-interacting ...
Central dopaminergic agonist properties of semisynthetic ergoline derivatives lergotrile, pergolide, bromocriptine and lisuride have been established. Some studies suggest that ergot alkaloids have the properties of mixed agonist-antagonist with regards to certain presynaptic and postsynaptic receptors.
Amantadine has dopaminergic effects through uncertain mechanisms of action. [24] [25] It is structurally related to other adamantanes like bromantane and rimantadine, which also have dopaminergic actions. [26] Bromantane can upregulate tyrosine hydroxylase (TH) and thereby increase dopamine production and this might be involved in its ...
This results in increased extracellular concentrations of dopamine and increase in dopaminergic neurotransmission. [ 1 ] DRIs are used in the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy for their psychostimulant effects, and in the treatment of obesity and binge eating disorder for their appetite suppressant effects.
These agents stimulate dopamine receptors. In doing so, they alleviate the symptoms associated with Parkinson's disease . Wikimedia Commons has media related to Dopamine agonists .
Other dopaminergic drugs that have been used or suggested in the treatment of disorders of diminished motivation include rasagiline (a selective monoamine oxidase B (MAO-B) inhibitor; but see more below), tolcapone (a centrally-acting catechol-O-methyltransferase (COMT) inhibitor), and amantadine (an indirectly acting dopaminergic agent that ...
The mechanisms of sympathomimetic drugs can be direct-acting (direct interaction between drug and receptor), such as α-adrenergic agonists, β-adrenergic agonists, and dopaminergic agonists; or indirect-acting (interaction not between drug and receptor), such as MAOIs, COMT inhibitors, release stimulants, and reuptake inhibitors that increase the levels of endogenous catecholamines.
1815 13491 Ensembl ENSG00000069696 ENSG00000276825 ENSMUSG00000025496 UniProt P21917 P51436 RefSeq (mRNA) NM_000797 NM_007878 RefSeq (protein) NP_000788 NP_031904 Location (UCSC) Chr 11: 0.64 – 0.64 Mb Chr 7: 140.87 – 140.88 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse The dopamine receptor D 4 is a dopamine D2-like G protein-coupled receptor encoded by the DRD4 gene on ...